BR112013007700A2 - formas em estado sólido de um potente inibidor de hcv - Google Patents
formas em estado sólido de um potente inibidor de hcvInfo
- Publication number
- BR112013007700A2 BR112013007700A2 BR112013007700A BR112013007700A BR112013007700A2 BR 112013007700 A2 BR112013007700 A2 BR 112013007700A2 BR 112013007700 A BR112013007700 A BR 112013007700A BR 112013007700 A BR112013007700 A BR 112013007700A BR 112013007700 A2 BR112013007700 A2 BR 112013007700A2
- Authority
- BR
- Brazil
- Prior art keywords
- solid state
- state forms
- hcv inhibitor
- potent hcv
- potent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
formas em estado sólido de um potente inibidor de hcv. a presente invenção refere-se a novas formas de sal de sódio do seguinte composto (1) e a métodos para a preparação do mesmo, a composição farmacêuticas do mesmo e a seu uso no tratamento de infecção por hepatite viral c (hcv).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38824210P | 2010-09-30 | 2010-09-30 | |
| PCT/US2011/052869 WO2012044520A1 (en) | 2010-09-30 | 2011-09-23 | Solid state forms of a potent hcv inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013007700A2 true BR112013007700A2 (pt) | 2019-09-24 |
Family
ID=44759789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013007700A BR112013007700A2 (pt) | 2010-09-30 | 2011-09-23 | formas em estado sólido de um potente inibidor de hcv |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8598183B2 (pt) |
| EP (1) | EP2621921A1 (pt) |
| JP (1) | JP2013543495A (pt) |
| KR (1) | KR20130108326A (pt) |
| CN (1) | CN103153987A (pt) |
| AP (1) | AP2013006733A0 (pt) |
| AR (1) | AR083256A1 (pt) |
| AU (1) | AU2011307346A1 (pt) |
| BR (1) | BR112013007700A2 (pt) |
| CA (1) | CA2813179A1 (pt) |
| CL (1) | CL2013000578A1 (pt) |
| CO (1) | CO6700844A2 (pt) |
| EA (1) | EA201300422A1 (pt) |
| EC (1) | ECSP13012552A (pt) |
| MA (1) | MA34548B1 (pt) |
| MX (1) | MX2013003551A (pt) |
| PE (1) | PE20131351A1 (pt) |
| SG (1) | SG188376A1 (pt) |
| TW (1) | TW201307327A (pt) |
| UY (1) | UY33632A (pt) |
| WO (1) | WO2012044520A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2013006733A0 (en) * | 2010-09-30 | 2013-02-28 | Boehringer Ingelheim Int | Solid state forms of a potent HCV inhibitor |
| AR089078A1 (es) * | 2011-12-06 | 2014-07-30 | Sanofi Sa | Formas cristalinas de [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida de acido 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-carboxilico |
| US20130261134A1 (en) * | 2012-03-30 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Mesylate salt forms of a potent hcv inhibitor |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1033128T2 (sl) | 1993-09-28 | 2012-02-29 | Scherer Gmbh R P | Izdelava mehke Ĺľelatinaste kapsule |
| US5821242A (en) * | 1996-06-06 | 1998-10-13 | Eli Lilly And Company | Anti-viral compounds |
| EP2335700A1 (en) * | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| US7582770B2 (en) * | 2004-02-20 | 2009-09-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| AU2006213769B2 (en) | 2005-02-11 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Process for preparing 2,3-disubstituted indoles |
| BRPI0618499A2 (pt) | 2005-11-09 | 2011-09-06 | Novartis Ag | processo para produção de composições farmacêuticas com um plastificante transitório |
| AP2013006733A0 (en) * | 2010-09-30 | 2013-02-28 | Boehringer Ingelheim Int | Solid state forms of a potent HCV inhibitor |
-
2011
- 2011-09-23 AP AP2013006733A patent/AP2013006733A0/xx unknown
- 2011-09-23 US US13/241,551 patent/US8598183B2/en active Active
- 2011-09-23 EP EP11764925.1A patent/EP2621921A1/en not_active Withdrawn
- 2011-09-23 BR BR112013007700A patent/BR112013007700A2/pt not_active IP Right Cessation
- 2011-09-23 SG SG2013015854A patent/SG188376A1/en unknown
- 2011-09-23 WO PCT/US2011/052869 patent/WO2012044520A1/en active Application Filing
- 2011-09-23 CA CA2813179A patent/CA2813179A1/en not_active Abandoned
- 2011-09-23 EA EA201300422A patent/EA201300422A1/ru unknown
- 2011-09-23 CN CN2011800471790A patent/CN103153987A/zh active Pending
- 2011-09-23 AU AU2011307346A patent/AU2011307346A1/en not_active Abandoned
- 2011-09-23 KR KR1020137008249A patent/KR20130108326A/ko not_active Application Discontinuation
- 2011-09-23 MA MA35773A patent/MA34548B1/fr unknown
- 2011-09-23 JP JP2013531669A patent/JP2013543495A/ja active Pending
- 2011-09-23 MX MX2013003551A patent/MX2013003551A/es not_active Application Discontinuation
- 2011-09-23 PE PE2013000628A patent/PE20131351A1/es not_active Application Discontinuation
- 2011-09-29 AR ARP110103617A patent/AR083256A1/es unknown
- 2011-09-29 UY UY0001033632A patent/UY33632A/es unknown
- 2011-09-29 TW TW100135337A patent/TW201307327A/zh unknown
-
2013
- 2013-02-28 CL CL2013000578A patent/CL2013000578A1/es unknown
- 2013-03-22 CO CO13057890A patent/CO6700844A2/es unknown
- 2013-04-15 EC ECSP13012552 patent/ECSP13012552A/es unknown
- 2013-10-30 US US14/067,218 patent/US20140057928A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN103153987A (zh) | 2013-06-12 |
| AR083256A1 (es) | 2013-02-13 |
| US8598183B2 (en) | 2013-12-03 |
| UY33632A (es) | 2012-04-30 |
| MA34548B1 (fr) | 2013-09-02 |
| EA201300422A1 (ru) | 2013-09-30 |
| US20140057928A1 (en) | 2014-02-27 |
| JP2013543495A (ja) | 2013-12-05 |
| CA2813179A1 (en) | 2012-04-05 |
| WO2012044520A1 (en) | 2012-04-05 |
| SG188376A1 (en) | 2013-04-30 |
| TW201307327A (zh) | 2013-02-16 |
| PE20131351A1 (es) | 2013-12-04 |
| MX2013003551A (es) | 2013-05-01 |
| ECSP13012552A (es) | 2013-06-28 |
| AU2011307346A1 (en) | 2013-02-21 |
| KR20130108326A (ko) | 2013-10-02 |
| EP2621921A1 (en) | 2013-08-07 |
| CL2013000578A1 (es) | 2013-08-02 |
| AP2013006733A0 (en) | 2013-02-28 |
| CO6700844A2 (es) | 2013-06-28 |
| US20120122887A1 (en) | 2012-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6390076A2 (es) | Inhibidores de hcv ns5a | |
| CO6390077A2 (es) | Inhibidores de hacv ns5a | |
| CY1123324T1 (el) | Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων | |
| BR112014011162A2 (pt) | derivados purínicos para o tratamento de infecções virais | |
| ECSP17064986A (es) | Compuestos antivirales | |
| BR112015000615A2 (pt) | purinas macrocíclicas para o tratamento de infecções virais | |
| BR112013003101A2 (pt) | inibidores do vírus da hepatite c | |
| ECSP13012622A (es) | Compuestos antivirales | |
| CL2012001230A1 (es) | Compuestos derivados de biciclos, inhibidores de la proteina ns5a; composicion farmaceutica que los comprende; uso en el tratamiento de la hepatitis c. | |
| BR112013002729A2 (pt) | inibidores de vírus de hepatite c | |
| BR112013028679A2 (pt) | inibidores do vírus da hepatite c | |
| BR122014013631B8 (pt) | compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos | |
| CO6450600A2 (es) | Inhibidores de anillo fusionado de hepatitis c | |
| BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
| ECSP11010878A (es) | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv. | |
| BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
| CL2007002284A1 (es) | Compuestos derivados de tetrazolilos macrociclicos; proceso de preparacion; composicion farmaceutica; y uso para tratar una infeccion viral de hepatitis c. | |
| EA201490654A1 (ru) | Новые ингибиторы вирусной репликации | |
| BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
| BR112012022812A2 (pt) | sais cristalinos de um potente inibidor de hcv | |
| JO3281B1 (ar) | مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي | |
| BR112013007700A2 (pt) | formas em estado sólido de um potente inibidor de hcv | |
| HK1131988A1 (en) | Polycyclic agents for the treatment of respiratory syncytial virus infections | |
| BR112014015582A8 (pt) | compostos antivirais | |
| SV2005001919A (es) | Compuestos nucleosidos para el tratamiento de infecciones virales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |